Literature DB >> 18250463

HMGB1 develops enhanced proinflammatory activity by binding to cytokines.

Yonggang Sha1, Jaroslaw Zmijewski, Zhiwei Xu, Edward Abraham.   

Abstract

High mobility group box 1 protein (HMGB1), originally characterized as a nuclear DNA-binding protein, has also been described to have an extracellular role when it is involved in cellular activation and proinflammatory responses. In this study, FLAG-tagged HMGB1 was inducibly expressed in the presence of culture media with or without added IL-1beta, IFN-gamma, or TNF-alpha. HMGB1 purified from cells grown in culture media alone only minimally increased cytokine production by MH-S macrophages and had no effect on murine neutrophils. In contrast, HMGB1 isolated from cells cultured in the presence of IL-1beta, IFN-gamma, and TNF-alpha had enhanced proinflammatory activity, resulting in increased production of MIP-2 and TNF-alpha by exposed cells. IL-1beta was bound to HMGB1 isolated from cells cultured with this cytokine, and purified HMGB1 incubated with recombinant IL-1beta acquired proinflammatory activity. Addition of anti-IL-1beta Abs or the IL-1 receptor antagonist to cell cultures blocked the proinflammatory activity of HMGB1 purified from IL-1beta-exposed cells, indicating that such activity was dependent on interaction with the IL-1 receptor. These results demonstrate that HMGB1 acquires proinflammatory activity through binding to proinflammatory mediators, such as IL-1beta.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18250463     DOI: 10.4049/jimmunol.180.4.2531

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  158 in total

1.  High mobility group box protein 1 (HMGB1)-partner molecule complexes enhance cytokine production by signaling through the partner molecule receptor.

Authors:  Hulda Sigridur Hreggvidsdóttir; Anna M Lundberg; Ann-Charlotte Aveberger; Lena Klevenvall; Ulf Andersson; Helena Erlandsson Harris
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

Review 2.  HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease.

Authors:  Helena Erlandsson Harris; Ulf Andersson; David S Pisetsky
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

Review 3.  Microparticles as mediators and biomarkers of rheumatic disease.

Authors:  David S Pisetsky; Anirudh J Ullal; Julie Gauley; Tony C Ning
Journal:  Rheumatology (Oxford)       Date:  2012-03-07       Impact factor: 7.580

4.  Immunomodulatory drugs regulate HMGB1 release from activated human monocytes.

Authors:  Hanna Schierbeck; Heidi Wähämaa; Ulf Andersson; Helena Erlandsson Harris
Journal:  Mol Med       Date:  2010-04-09       Impact factor: 6.354

5.  Chondrocyte innate immune myeloid differentiation factor 88-dependent signaling drives procatabolic effects of the endogenous Toll-like receptor 2/Toll-like receptor 4 ligands low molecular weight hyaluronan and high mobility group box chromosomal protein 1 in mice.

Authors:  Ru Liu-Bryan; Robert Terkeltaub
Journal:  Arthritis Rheum       Date:  2010-07

Review 6.  HMGB1 and microparticles as mediators of the immune response to cell death.

Authors:  David S Pisetsky; Julie Gauley; Anirudh J Ullal
Journal:  Antioxid Redox Signal       Date:  2011-05-05       Impact factor: 8.401

7.  HMGB1 contributes to allergen-induced airway remodeling in a murine model of chronic asthma by modulating airway inflammation and activating lung fibroblasts.

Authors:  Changchun Hou; Jinliang Kong; Yue Liang; Hong Huang; Hanchun Wen; Xiaowen Zheng; Lihong Wu; Yiqiang Chen
Journal:  Cell Mol Immunol       Date:  2014-08-25       Impact factor: 11.530

8.  The IKKα-dependent NF-κB p52/RelB noncanonical pathway is essential to sustain a CXCL12 autocrine loop in cells migrating in response to HMGB1.

Authors:  Richard R Kew; Marianna Penzo; David M Habiel; Kenneth B Marcu
Journal:  J Immunol       Date:  2012-01-27       Impact factor: 5.422

9.  Endogenous HMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-α/JNK.

Authors:  Hu Xu; Yongwei Yao; Zhaoliang Su; Yunbo Yang; Raymond Kao; Claudio M Martin; Tao Rui
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-12-24       Impact factor: 4.733

10.  Curcumin: a double hit on malignant mesothelioma.

Authors:  Jill M Miller; Joyce K Thompson; Maximilian B MacPherson; Stacie L Beuschel; Catherine M Westbom; Mutlay Sayan; Arti Shukla
Journal:  Cancer Prev Res (Phila)       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.